GI Partners completes acquisition of Clinical Ink

Private investment firm GI Partners has completed the previously announced acquisition of Clinical Ink, a global clinical trial technology company.

Headquartered in Horsham, Pennsylvania, Clinical Ink offers data certainty from source to submission during clinical trials. The company’s Lumenis eSource clinical technology is a suite of solutions for capturing and integrating clinical trial electronic study data from sites, clinicians, and patients in real time. Through configurable direct data capture (DDC), electronic clinical outcome assessment (eCOA), electronic patient reported outcomes (ePRO), and eConsent modules, the company’s eSource Ecosystem has been deployed across 300 studies, in all Phases (I–IV).

 
In partnership with the company’s senior management team, GI Partners plans to accelerate Clinical Ink’s innovation in clinical trial workflow solutions. NovaQuest, an existing shareholder in Clinical Ink, will continue as a minority investor in the business.
 
Cain Brothers served as financial advisor to GI Partners in the transaction, while Ropes & Gray served as legal advisor. Baird served as financial advisor to Clinical Ink in the transaction, while Wyrick Robbins served as legal advisor.